South Korean vaccine and biotech company SK Bioscience's (KRX:302440) Germany-based CDMO subsidiary IDT Biologika is ramping up its global outreach through major industry events.
The company recently highlighted its end-to-end services in viral vaccines, gene and immune therapeutics, and aseptic injectables at the BioProcess International Europe (BPI Europe) in Hamburg, SK Bioscience said Tuesday.
Shares of SK Bioscience rose nearly 2% in recent trade on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.